EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites36
Patients1063

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	556
New Zealand	204
Finland	112
Switzerland	59
Saudi Arabia	47
Belgium	35
Ireland	31
Slovenia	12
Germany	7
Total	1063